Xylometazoline


Concise Prescribing Info
Indications/Uses
Nasal congestion.
Dosage/Direction for Use
Adult: Nasal As 0.1% drops: Apply 2-3 drops bid-tid into each nostril. As 0.1% metered-dose spray: 1 spray in each nostril 1-3 times daily. As 0.1% spray: 1 spray bid-tid into each nostril. Max duration: 5 days.
Contraindications
Undergo trans-sphenoidal hypophysectomy or surgery exposing dura mater, narrow angle glaucoma, atrophic rhinitis. Children <6 years.
Special Precautions
Patient with CV disease, hypertension, diabetes mellitus, hyperthyroidism, prostatic hyperplasia or urinary obstruction. Elderly, children >6 years. Pregnancy and lactation. Patient Counselling Avoid excessive or prolonged use.
Adverse Reactions
Significant: Local irritation, burning sensation in the nose and throat, rebound congestion. Hallucinations, restlessness, sleep disturbances in children. Rarely, transient visual impairment, tachycardia. Cardiac disorders: Palpitations. Gastrointestinal disorders: Nausea. General disorders and administration site conditions: Mucosal dryness. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Dry nose, nasal discomfort.
Drug Interactions
Enhanced adverse effects with other sympathomimetics. Risk of hypertensive crisis with MAOIs or TCAs.
ATC Classification
R01AB06 - xylometazoline ; Belongs to the class of topical sympathomimetic combination preparations, excluding corticosteroids. Used as nasal decongestants.
R01AA07 - xylometazoline ; Belongs to the class of topical sympathomimetic agents used as nasal decongestants.
S01GA03 - xylometazoline ; Belongs to the class of sympathomimetics used as ophthalmologic decongestants.
Disclaimer: This information is independently developed by CIMS based on xylometazoline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in